Carmine Therapeutics is developing allogeneic, redosable, non-viral gene therapies to treat diseases for which a high unmet medical need exists. The company’s technology harnesses the natural properties of human red blood cells (RBCs) to produce extracellular vesicles (EVs), allowing the delivery of large payloads of genetic material, resulting in high-amplitude, durable transgene expression to replace missing or mutat

Carmine Therapeutics: Gene Therapy 3.0
januari 03, 2023by Reacties uitgeschakeld voor Carmine Therapeutics: Gene Therapy 3.0
Previous Post
TTP nurtured by Pakistan army fuels insurgency in Khyber Pakhtunkhwa
Next Post
Power Crisis, frequent load shedding continues to trigger protests in Gilgit Baltistan